CA-RECOVER
14.10.2021 16:07:08 CEST | Business Wire | Press release
Global fashion retailer REVOLVE has partnered with Recover™, leading producer in recycled cotton fiber, to introduce a sustainable denim collection with REVOLVE-owned brand Lovers and Friends.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005745/en/
Recover™ is an innovative textile fiber producer that has been pioneering sustainable materials and recycling since 1947. The company recycles post-industrial and post-consumer cotton waste, replacing the need to cultivate cotton, dramatically reducing water waste, limiting the use of dyes through its RColorBlend system, and reducing textile landfill waste.
Launched today, the range features 14 styles of jeans, each produced with a minimum of 15% Recover™ recycled cotton fiber made from post-consumer denim.
The pairing of the valuable resources Recover™ provides with Lovers and Friends underscores REVOLVE’s commitment to sustainable fashion, and leading the change towards a more circular, and enduring fashion system.
“REVOLVE has a responsibility to contribute positively to the longevity of our industry and ecosystem, and for us, this process begins at home. We have worked with thousands of brands and suppliers, and Recover™ is unparalleled in its expertise and long-term focus. We are proud to partner with this multigeneration, family-owned business to deliver the strongest messaging and product to our consumers with one of our most recognizable owned brands, Lovers and Friends.” - Michael Mente, Co-CEO and Co-Founder REVOLVE Group.
“It is great to launch this sustainable collection today with such an iconic American brand and denim product. By incorporating Recover´s lowest-impact, highest-quality recycled fiber into the Lovers and Friends denim line we have created a strong collaboration that is helping to bring sustainable fashion closer to the consumer. Recover™ aims to scale its recycled cotton fiber production to help more brands meet their sustainable goals and achieve circular fashion for all.” - Alfredo Ferre, CEO Recover™
Recover™ has already supplied its recycled cotton and cotton blend fibers to illustrious brands such as Wrangler, H&M Group, Tommy Hilfiger, G-Star, The North Face, Billabong and Primark among many others during its rich history.
“Recover™ is building a strong ingredient brand, with the mission to dramatically enhance the environmental value of the garment for the final customer. We’ve taken special care in the way we inform them about the impact of this collection in collaboration with REVOLVE. The hang tag includes a QR code that leads to more information about the environmental savings, such as water, and compares them to day-to-day activities, like the number of showers, to make them more understandable.” – Boris Mercier, Marketing Director Recover™
By adding REVOLVE and Lovers and Friends to its portfolio, Recover™ moves one step closer to achieving its mission of “circular fashion for all”.
Price Range: $128-$158. Available at REVOLVE.com
About Recover™
Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.
As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets. Recover™ was honored in Fast Company ’s Innovation by Design Awards for 2021 in the Sustainability and Materials categories.
For more information, visit www.recoverfiber.com and follow @recoverfiber on social media.
About REVOLVE
REVOLVE is the next-generation fashion retailer for Millennial and Generation Z consumers. As a trusted, premium lifestyle brand and a go-to source for discovery and inspiration, REVOLVE delivers an engaging customer experience from a vast yet curated offering of over 45,000 products. Founded in Los Angeles in 2003 by co-CEOs, Michael Mente and Mike Karanikolas, REVOLVE’s family of brands includes their luxury offering, FWRD.com, and a portfolio of owned brands such as Lovers and Friends, Tularosa, NBD and RAYE. For more information, please visit www.revolve.com , or find us on Instagram , Twitter, Pinterest, and Facebook.
About Lovers and Friends
Inspired by the laid back Los Angeles lifestyle in which the brand was founded, Lovers and Friends exudes effortless style and wearability, creating a signature sexy-meets-chic look with a California-cool sensibility. Lovers and Friends is designed for the girl who is a go-getter and fun-seeker. Every trend-inspired outfit is perfectly curated for her event-filled social schedule, whether she's meeting her girls for brunch or jet-setting to another coast. Sometimes sassy, sometimes sweet but always chic - she is both a LOVER and a FRIEND.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005745/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom